Table 1. Baseline Characteristics of Patients.

Number of patients	104
Sex (male/female)	21/83
Age (years) (median; 25.0–75.0%)	54 (45–66)
TSH (mIU/L) (median; 25.0–75.0%)	1.2 (0.9–2)
Non-spongiform/spongiform	46/58
Energy delivered (J) (Median; 25.0–75.0%)	6179.5 (4057–8044)
Energy delivered/mL (Median; 25.0–75.0%)	481.5 (370–620)
Nodule volume at baseline (mL) (Median; 25.0–75.0%)	12.5 (8–18)
Small nodules (≤ 10 mL) (%)	41 (39.4)
Medium nodules (11–30 mL) (%)	57 (54.8)
Large nodules (> 30 mL) (%)	6 (5.8)
VRR at 12-month follow-up (%) (median; 25.0–75.0%)	60.5 (47–71)

TSH = thyroid-stimulating hormone, VRR = volume reduction ratio